The Biden administration’s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry’s price negotiators is backfiring, pharmacists say.
Motif Neurotech Conducts First-In-Human Brain Stimulation for Treatment-resistant Depression
What You Should Know: Motif Neurotech, a neurotechnology company developing minimally invasive bioelectronics for mental health, announced new research published to the preprint server medrxiv that demonstrates